Cancer Medicine (Dec 2023)

Increased STX3 transcript and protein levels were associated with poor prognosis in two independent cohorts of esophageal squamous cell carcinoma patients

  • Takahiro Shinozuka,
  • Mitsuro Kanda,
  • Yusuke Sato,
  • Dai Shimizu,
  • Chie Tanaka,
  • Shinichi Umeda,
  • Yoshikuni Inokawa,
  • Norifumi Hattori,
  • Masamichi Hayashi,
  • Goro Nakayama,
  • Yasuhiro Kodera

DOI
https://doi.org/10.1002/cam4.6770
Journal volume & issue
Vol. 12, no. 24
pp. 22185 – 22195

Abstract

Read online

Abstract Background Some conventional prognostic biomarkers for esophageal squamous cell carcinoma (ESCC) have the disadvantage that they have only been investigated at the level of either mRNA or protein levels or only in individual cohorts. Associations between Syntaxin 3 (STX3) expression and malignancy have been reported in several tumor types but not in ESCC. Here, we investigated the levels of both STX3 mRNA and protein, and its prognostic potential in two independent cohorts of patients with ESCC. Methods STX3 mRNA levels were examined in surgical specimens by quantitative PCR in a cohort that included 176 ESCC patients. STX3 protein levels were investigated in surgically resected ESCC tissues by immunohistochemistry using tissue microarrays in a different cohort of 177 ESCC patients. Correlations were analyzed between the expression of STX3 mRNA and protein with clinicopathological factors and long‐term prognosis. Results Quantitative PCR indicated a significant association between high level of STX3 mRNA expression and lymph node involvement, pathological stage, and poor overall survival. The multivariate analysis demonstrated that high STX3 mRNA expression was independently associated with poor overall survival outcomes. Immunohistochemistry revealed that STX3 protein expression in ESCC tissues and high STX3 protein expression were also significantly correlated with unfavorable overall survival. Conclusions Overexpression of STX3 mRNA and protein may serve as potential prognostic biomarkers for ESCC patients.

Keywords